NASDAQ:SELB - Selecta Biosciences Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.38 +2.04 (+14.23 %) (As of 09/20/2018 02:21 PM ET)Previous Close$14.34Today's Range$14.40 - $16.545052-Week Range$7.95 - $24.02Volume290,756 shsAverage Volume93,487 shsMarket Capitalization$314.67 millionP/E Ratio-5.12Dividend YieldN/ABeta-3.39 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis. It is also developing SEL-403 product candidate, a combination therapy comprising SVP-rapamycin and LMB-100, which is in Phase I clinical trial for the treatment of patients with malignant pleural or peritoneal mesothelioma; and SELA-070, a nicotine vaccine product candidate that is in Phase I clinical trial for smoking cessation and relapse prevention. In addition, the company engages in the development of gene therapy product candidates that are in preclinical development for rare inborn errors of metabolism, including SEL-302, a lead gene therapy program for the treatment methylmalonic academia; and SEL-313, a gene therapy product candidate to treat ornithine transcarbamylase deficiency. Selecta Biosciences, Inc. has license and collaboration agreements with Spark Therapeutics, Massachusetts Institute of Technology, Shenyang Sunshine Pharmaceutical Co., Ltd., BIND Therapeutics, Inc., and Massachusetts Eye and Ear Infirmary, as well as research collaboration agreements with National Cancer Institute. The company was founded in 2007 and is headquartered in Watertown, Massachusetts. Receive SELB News and Ratings via Email Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:SELB CUSIPN/A Webwww.selectabio.com Phone617-923-1400 Debt Debt-to-Equity Ratio0.87 Current Ratio4.96 Quick Ratio4.96 Price-To-Earnings Trailing P/E Ratio-5.12 Forward P/E Ratio-5.34 P/E GrowthN/A Sales & Book Value Annual Sales$210,000.00 Price / Sales1,747.20 Cash FlowN/A Price / CashN/A Book Value$2.32 per share Price / Book7.06 Profitability EPS (Most Recent Fiscal Year)($3.20) Net Income$-65,320,000.00 Net Margins-31,556.04% Return on Equity-150.84% Return on Assets-73.66% Miscellaneous Employees64 Outstanding Shares22,400,000Market Cap$314.67 million Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions What is Selecta Biosciences' stock symbol? Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB." How were Selecta Biosciences' earnings last quarter? Selecta Biosciences Inc (NASDAQ:SELB) posted its earnings results on Wednesday, August, 8th. The company reported ($0.84) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.16. Selecta Biosciences had a negative return on equity of 150.84% and a negative net margin of 31,556.04%. View Selecta Biosciences' Earnings History. When is Selecta Biosciences' next earnings date? Selecta Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November, 6th 2018. View Earnings Estimates for Selecta Biosciences. What price target have analysts set for SELB? 5 Wall Street analysts have issued 12-month target prices for Selecta Biosciences' shares. Their predictions range from $24.00 to $40.00. On average, they expect Selecta Biosciences' share price to reach $31.75 in the next year. This suggests a possible upside of 105.4% from the stock's current price. View Analyst Price Targets for Selecta Biosciences. What is the consensus analysts' recommendation for Selecta Biosciences? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences. What are Wall Street analysts saying about Selecta Biosciences stock? Here are some recent quotes from research analysts about Selecta Biosciences stock: 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (8/29/2018) 2. Mizuho analysts commented, "We do not see quarterly earnings as the most meaningful indicator of value for development stage biotechs. Selecta will present data from the Phase 2 trial of SEL-212 for the five monthly dose cohorts at the Rheumatology (ACR) meeting on October 19-24, 2018. We think this is likely the biggest catalyst for the shares in 2018 and we view the probability of success as favorable. Phase 3 trial preparations are underway. A head-to-head trial with standard of care Krystexxa is also planned which we believe could be an important differentiator for SEL-212." (8/9/2018) 3. Canaccord Genuity analysts commented, "We expect Selecta to present positive 5-dose Phase 2 combination data for SEL-212 in severe gout during 3Q18, and see significant upside for the stock. Selecta is likely to present data from multiple dosing cohorts, with up to n=20 patients from each cohort. We suspect focus will be on the 0.15 mg/kg SVP-rapamycin + 0.20 pegsiticase dose, but await upcoming data. We see little reason that SEL-212 will not reproduce data at 5 months similar to that seen at 3 months, where ~80% Serum Uric Acid control was shown." (7/11/2018) Who are some of Selecta Biosciences' key competitors? Some companies that are related to Selecta Biosciences include Omeros (OMER), Retrophin (RTRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Intra-Cellular Therapies (ITCI), Karyopharm Therapeutics (KPTI), Alder Biopharmaceuticals (ALDR), Athenex (ATNX), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), Dicerna Pharmaceuticals (DRNA), Apellis Pharmaceuticals (APLS), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA) and Geron (GERN). Who are Selecta Biosciences' key executives? Selecta Biosciences' management team includes the folowing people: Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 49)Dr. Werner Cautreels, Pres, CEO & Director (Age 66)Dr. John H. Leaman, CFO, Head of Corp. Strategy & Treasurer (Age 45)Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 50)Dr. Ulrich H. von Andrian-Werburg, Co-Founder and Co-Chair of the Scientific Advisory Board When did Selecta Biosciences IPO? (SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. Has Selecta Biosciences been receiving favorable news coverage? News headlines about SELB stock have been trending somewhat positive on Thursday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Selecta Biosciences earned a daily sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Selecta Biosciences. Who are Selecta Biosciences' major shareholders? Selecta Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (3.96%), Vivo Capital LLC (3.49%), FMR LLC (1.25%), Wasatch Advisors Inc. (1.05%), Northern Trust Corp (0.70%) and Millennium Management LLC (0.53%). Company insiders that own Selecta Biosciences stock include Amir Nashat, David Abraham, David Siewers, Earl Sands, Edwin M Kania, Jr, Lloyd P Johnston, Peter Keller, Takashi Kei Kishimoto, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Institutional Ownership Trends for Selecta Biosciences. Which institutional investors are selling Selecta Biosciences stock? SELB stock was sold by a variety of institutional investors in the last quarter, including Vivo Capital LLC, FMR LLC, Alps Advisors Inc. and Alps Advisors Inc.. Company insiders that have sold Selecta Biosciences company stock in the last year include Amir Nashat and David Siewers. View Insider Buying and Selling for Selecta Biosciences. Which institutional investors are buying Selecta Biosciences stock? SELB stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Millennium Management LLC, Proxima Capital Management LLC, Wasatch Advisors Inc., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp and Schwab Charles Investment Management Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Earl Sands, Timothy A Springer, Timothy C Barabe and Werner Cautreels. View Insider Buying and Selling for Selecta Biosciences. How do I buy shares of Selecta Biosciences? Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Selecta Biosciences' stock price today? One share of SELB stock can currently be purchased for approximately $15.4548. How big of a company is Selecta Biosciences? Selecta Biosciences has a market capitalization of $314.67 million and generates $210,000.00 in revenue each year. The company earns $-65,320,000.00 in net income (profit) each year or ($3.20) on an earnings per share basis. Selecta Biosciences employs 64 workers across the globe. How can I contact Selecta Biosciences? Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected] MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 159 (Vote Outperform)Underperform Votes: 139 (Vote Underperform)Total Votes: 298MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 9/20/2018 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?